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S110 Chronic Kidney DiseaseConclusion: The prevalence of hypertension in our inpatients was very
high. Most of the patients with hypertension were treated by two or
more types of antihypertensive drugs. The most frequently used antihyper-
tensive drug was CCB. Less than half of the patients used RASI to treat hy-
pertension and the control of hypertension was poor. But we improved the
situation of SBP and the up-to-standard rate of blood pressure by
hospitalization.http://dx.doi.org/10.1016/j.hkjn.2015.09.155
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Objective: To assess the efficacy and safety of dipeptidyl peptidase-4
(DPP-4) inhibitors compared with placebo or with other hypoglycaemic
drugs in patients with type 2 diabetes mellitus and severe renal impair-
ment (RI).
Methods: A meta-analysis of RCTs was performed in adults with type 2 dia-
betes mellitus and severe RI, and assessed the comparative effect of DPP-4
inhibitors on HbA1C and fasting blood glucose (FPG). Safety was evaluated
based on analysis of percentage of hypoglycemia, occurrence of any adverse
events (AE) and any serious adverse events (SAE), the incidence of periph-
eral edema, urinary tract infection, diarrhea and death.
Results: Five RCTs and 503 patients were included. Compared with placebo
or no treatment, DPP-4 inhibitors were associated with a larger decline in
HbA1c (MD 0.57; 95% CI 0.73 to 0.41; P < 0.01) but not with FPG (MD
0.26; 95% CI 1.40 to 0.8; P Z 0.66). Compared with glipizide monother-
apy, no significant difference reached in HbA1c (MD 0.15; 95% CI 0.19 to
0.49; PZ 0.38) and FPG (MD 0.26; 95% CI 1.16 to 0.64; PZ 0.57). Similar
odds of any or serious adverse events between DPP-4 inhibitors and
comparators.
Conclusion: In type 2 diabetes mellitus and severe RI, treatment with DPP-4
inhibitors is safe and can effectively low HbA1c.http://dx.doi.org/10.1016/j.hkjn.2015.09.156
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Table 1 Multivariate analysis of different levels of eGFR associated with all
Baseline lev
 90
HR (95% Cl) p-value HR (95 %Cl)
Unadjusted Ref. 1.256 (1.156-1
Adjusted
Model 1 Ref. 0.959 (0.876-1
Model 2 Ref. 1.005 (0.916-1
Model 3 Ref. 1.051 (0.954-1
Model 4 Ref. 1.062 (0.946-1
Model 1: Adjusted for age, sex.
Model 2: Model 1+ BMI, HP, CVD, DM, smoking, drinking.
Model 3: Model 2 + ALB, ALT, AST, TG, GLU, hemoglobin, CRP.
Model 4: Model 3 + treatment (chemotherapy, surgery, combined treatment, b5Institute of Public Health, National Yang-Ming University, Kaohsiung,
Taiwan
Objective: Atrial fibrillation (AF) increases risk of thromboembolism events
and is prevalent among chronic kidney disease (CKD) patients. However, the
impact of AF on the mortality, acute coronary syndrome (ACS), and renal
function decline in CKD population are rare investigated. We determined
the association between incident AF and risk of death, cardiovascular
events, and end-stage renal disease (ESRD) among adults with CKD using na-
tional health insurance database in Taiwan.
Methods: CKD patients enrolled in the Pre-end stage renal disease (Pre-ESRD)
care management program,  18 years patients who were at least one outpa-
tient diagnosis codes (ICD-9 codes 585, 581.9) or at least one inpatient diagnosis
codes and free of any dialysis or renal transplant from Jan 1st 2007 to Dec 31st
2011 were included. CKD patients with AF were 1:5matched to control subjects
without AF by age, sex, urbanization, and socioeconomic status. Cox propor-
tional hazards regression models were used to estimate hazard ratios (HRs) for
all-cause mortality, cardiovascular events, and renal function decline analysis.
Results:Weincluded1995CKDpatientswithAF;of these,746 (37.4%)death,148
(7.4%)hadACS,222 (11.1%)had strokeor thromboembolism,and207 (10.4%)had
rapid eGFR decline. As compared with the CKD without AF subjects, those with
AFwasassociatedwithmultivariate-adjustedHRsof1.64 (95%CI, 1.49e1.81) for
death, 1.41 (95% CI, 1.14e1.74) for ACS, 2.15 (95% CI, 1.79e2.58) for stroke or
thromboembolism, 1.50 (95% CI, 1.31e1.73) for ESRD, and 3.35 (95% CI,
2.80e4.00) for rapid eGFR decline after adjusting comorbid disorders, clinical
characteristics, medications, and competing risk of mortality.
Conclusion: AF is independently associated with increased risk of developing
ACS, thromboembolism, and progression to ESRD in adults with CKD.http://dx.doi.org/10.1016/j.hkjn.2015.09.157
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Objective: To estimate the prevalence and the effect of abnormal renal
function in newly solid cancer patients.
Methods: From January 1, 2010 to December 31, 2010, 9128 patients with
newly diagnosed solid cancer in a cancer center were retrospectively stud-
ied. Renal function was calculated for each patients using Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula at the time of diag-
nosis. The prevalence of renal insufficiency (RI) and effect of RI on mortality
according to different treatments in these patients were investigated.
Results: Of the total 9128 patients, 31.7% had RI (eGFR < 90 ml/min/
1.73 m2), 2.9% had CKD (eGFR < 60 ml/min/1.73 m2), and 0.2% had
eGFR < 30 ml/min/1.73 m2. Patients with lymphoma and lung cancer have
the highest prevalence of CKD (4.3%, 4.1% respectively). Of the total pa-
tients, the number of patients who received treatment of surgery, chemo-
therapy, combination of surgery and chemotherapy, and best support care
(BSC) was 3131, 3110, 2035, 852, respectively. After multivariate analysis,
eGFR < 60 ml/min/1.73 m2 was found to be an independent risk factor for-cause mortality.
els of eGFR (ml/min/1.73m2)
60e89 <60
p-value HR (95% Cl) p-value
.365) <0.001 1.969 (1.630-2.379) <0 001
.049) 0.364 1.361 (1.121-1.653) 0.002
.103) 0.917 1.413 (1.155-1.729) 0.001
.158) 0.314 1.259 (1.021-1.553) 0.031
.171) 0.222 1.272 (1.031-1.570) 0.025
est supportive care).
